前列腺癌小鼠模型中PSMA靶向放射配体治疗耐药机制研究
该研究在前列腺癌小鼠模型中评估PSMA靶向放射配体治疗的疗效,并通过蛋白质组和磷酸化蛋白质组分析揭示耐药相关信号通路改变。结果显示治疗以剂量依赖方式显著改善疾病控制,并激活DNA损伤应答、TP53、雄激素受体、PI3K/AKT及MYC等信号;TP53敲除肿瘤对治疗敏感性降低,提示TP53参与介导治疗反应。
要点
- PSMA靶向RLT以剂量依赖方式显著改善小鼠前列腺癌疾病控制。
- 治疗后蛋白质组揭示DNA损伤应答、TP53、AR、PI3K/AKT及MYC信号改变。
- TP53敲除肿瘤对PSMA靶向RLT敏感性低于亲本肿瘤。
核心结论
- 研究识别出可能介导前列腺癌小鼠模型对PSMA靶向放射配体治疗耐药的信号改变。
- 数据支持开发合理的协同联合放射配体治疗方案以改善前列腺癌患者结局。
研究设计与样本
- 在C4-2或C4-2 TP53-/-荷瘤非肥胖糖尿病scid γ小鼠中评估PSMA靶向放射配体治疗的疗效。
- 通过肿瘤体积测量、进展时间和生存评估治疗效果。
- 治疗两天后采用质谱分析肿瘤蛋白质组和磷酸化蛋白质组。
主要发现
- PSMA靶向放射配体治疗以剂量依赖方式显著改善疾病控制。
- 蛋白质组和磷酸化蛋白质组数据揭示基因毒性应激反应通路激活。
- 激活通路涉及DNA损伤/复制应激反应失调、TP53、雄激素受体、磷脂酰肌醇-3-激酶/AKT和MYC信号。
- C4-2 TP53-/-肿瘤对PSMA靶向放射配体治疗的敏感性低于亲本对照肿瘤。
临床怎么用
- 研究提示TP53状态可能影响前列腺癌对PSMA靶向放射配体治疗的反应性。
- 识别出的信号改变为设计放射配体治疗联合策略提供依据。
局限性
- 研究基于小鼠前列腺癌模型,结论向临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is effective against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the underlying resistance mechanisms represents a key barrier to development of more effective RLT. We investigate the proteome and phosphoproteome in a mouse model of PCa to identify signaling adaptations triggered by PSMA RLT. Methods: Therapeutic efficacy of PSMA RLT was assessed by tumor volume measurements, time to progression, and survival in C4-2 or C4-2 TP53-/- tumor-bearing nonobese diabetic scid γ-mice. Two days after RLT, the proteome and phosphoproteome were analyzed by mass spectrometry. Results: PSMA RLT significantly improved disease control in a dose-dependent manner. Proteome and phosphoproteome datasets revealed activation of genotoxic stress response pathways, including deregulation of DNA damage/replication stress response, TP53, androgen receptor, phosphatidylinositol-3-kinase/AKT, and MYC signaling. C4-2 TP53-/- tumors were less sensitive to PSMA RLT than were parental counterparts, supporting a role for TP53 in mediating RLT responsiveness. Conclusion: We identified signaling alterations that may mediate resistance to PSMA RLT in a PCa mouse model. Our data enable the development of rational synergistic RLT-combination therapies to improve outcomes for PCa patients.
引用
- Stuparu AD, Capri JR, Meyer CAL, et al. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. J Nucl Med. 2020. PMID: 33277393. doi:10.2967/jnumed.120.256263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。